Literature DB >> 30408566

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Sarah A Holstein1, J Christine Ye2, Alan Howard3, Manisha Bhutani4, Nicole Gormley5, Theresa Hahn6, Jens Hillengass6, Amrita Krishnan7, C Ola Landgren8, Nikhil C Munshi9, Stefania Oliva10, Roger G Owen11, Marcelo C Pasquini12, Noemi Puig13, Niels Weinhold14, Katja Weisel15, Philip L McCarthy6.   

Abstract

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.
Copyright © 2018 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Keywords:  Autologous stem cell transplantation; Endpoint; Immune profiling; Minimal residual disease; Multiple myeloma

Mesh：

Substances：

Year:  2018        PMID： 30408566      PMCID： PMC6445685          DOI： 10.1016/j.bbmt.2018.11.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  9 in total

1.  Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.

Authors:  Sarah A Holstein; Vera J Suman; Kouros Owzar; Katelyn Santo; Don M Benson; Thomas C Shea; Thomas Martin; Margarida Silverman; Luis Isola; Ravi Vij; Bruce D Cheson; Charles Linker; Kenneth C Anderson; Paul G Richardson; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-20       Impact factor: 5.742

Review 2.  Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Authors:  Shalin Kothari; Jens Hillengass; Philip L McCarthy; Sarah A Holstein
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

3.  Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Authors:  Sarah A Holstein; Fotis Asimakopoulos; Abdel Kareem Azab; Giada Bianchi; Manisha Bhutani; Leslie A Crews; Tom Cupedo; Hannah Giles; Sarah Gooding; Jens Hillengass; Lukas John; Shari Kaiser; Lydia Lee; Kylee Maclachlan; Marcelo C Pasquini; Flavia Pichiorri; Nina Shah; Monica Shokeen; Brian R Shy; Eric L Smith; Raluca Verona; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2022-05-21

4.  Immunophenotypic Characteristics of Bone Marrow Microenvironment Cellular Composition at the Biochemical Progression of Multiple Myeloma.

Authors:  Agnieszka Krzywdzińska; Bartosz Puła; Donata Szymczak; Aneta Milanowska; Agnieszka Szeremet; Krzysztof Jamroziak
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

Review 5.  Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Zaid Al-Kadhimi; Luciano J Costa; Theresa Hahn; Parameswaran Hari; Jens Hillengass; Allison Jacob; Nikhil C Munshi; Stefania Oliva; Marcelo C Pasquini; Qian Shi; Edward A Stadtmauer; Stephanie L Waldvogel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-14       Impact factor: 5.742

Review 6.  Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D Cohen; Luciano J Costa; Madhav V Dhodapkar; Francesca Gay; Nicole Gormley; Damian J Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C Pasquini; Noemi Puig; G David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A Shah; Qian Shi; Andrew Spencer; Vera J Suman; Saad Z Usmani; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

Review 7.  The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

Authors:  Sarah A Holstein; Nizar Bahlis; P Leif Bergsagel; Manisha Bhutani; Niccolo Bolli; Carrie Brownstein; Pierre Demolis; David Foureau; Francesca Gay; Irene M Ghobrial; Nicole Gormley; Jens Hillengass; Martin Kaiser; Marcela V Maus; J Joseph Melenhorst; Maximilian Merz; Michael O Dwyer; Bruno Paiva; Marcelo C Pasquini; Nina Shah; Sandy W Wong; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2021-06-06

Review 8.  Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.

Authors:  Alessandra Romano; Giuseppe Alberto Palumbo; Nunziatina Laura Parrinello; Concetta Conticello; Marina Martello; Carolina Terragna
Journal:  Front Oncol       Date:  2019-08-20       Impact factor: 6.244

Review 9.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.